bendamustine chemotherapy

January 23, 2020

Polivy Triple Combo Approved in Europe for Select Patients with Advanced DLBCL

News

The European Commission has conditionally approved Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine, to treat people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for a hematopoietic (blood) stem cell transplant (HSCT). ... Read more

October 10, 2017

Gazyva Reduces Risk of Disease Progression in Follicular Lymphoma Patients, Clinical Trial Finds

News

Interim analysis of the GALLIUM (NCT01332968) clinical trial shows that treatment with Gazyva plus chemotherapy improves progression-free survival in patients with advanced, CD20-positive, untreated follicular lymphoma. The GALLIUM trial set ... Read more

March 1, 2016May 13, 2016

FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan

News

Genentech announced that the the U.S. Food and Drug Administration (FDA) has approved the combination of Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva for the treatment of people with follicular lymphoma who were ... Read more